Why the study?
Due to the lack of effective early diagnosis and treatment methods, the molecular mechanisms of myocardial remodelling require in-depth exploration.
Does MBNL1 regulate isoproterenol-induced myocardial remodelling in vitro and in vivo?
Does MBNL1 regulate isoproterenol-induced myocardial remodelling in vitro and in vivo?
MBNL1 promotes isoproterenol-induced cardiac hypertrophy and fibrosis by stabilizing Myocardin mRNA, suggesting it as a potential therapeutic target for myocardial remodelling.
Answers are grounded in this paper and cite their sources.
MBNL1 may represent a novel target in hypertrophy; leaves open clinical translation from animal data.
Myocardial remodelling is a common phenomenon in cardiovascular diseases, which threaten human health and the quality of life. Due to the lack of effective early diagnosis and treatment methods, the molecular mechanism of myocardial remodelling should be explored in depth. In this study, we observed the high expression of MBNL1 in cardiac tissue and peripheral blood of an isoproterenol (ISO)-induced cardiac hypertrophy mouse model. MBNL1 promoted ISO-induced cardiac hypertrophy and fibrosis by stabilizing Myocardin mRNA in vivo and in vitro. Meanwhile, an increase in MBNL1 may induce the apoptosis of cardiomyocytes treated with ISO via TNF-α signalling. Interestingly, MBNL1 can be activated by p300 in cardiomyocytes treated with ISO. At last, Myocardin can reverse activate the expression of MBNL1. These results suggest that MBNL1 may be a potential target for the early diagnosis and clinical treatment of myocardial remodelling.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: